Screener
Summit Therapeutics SMMT Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 775,458,141 | 738,076,003 |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | 84 | (145) |
| Unrealized loss on short-term investments | (176) | (133) |
| Comprehensive loss | $(189,516) | $(63,191) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's shares (diluted)?
- Summit Therapeutics (SMMT) reported shares (diluted) of 775.5M in Q1 2026.
- How has Summit Therapeutics's shares (diluted) changed year-over-year?
- Summit Therapeutics's shares (diluted) increased by 5.1% year-over-year, from 738.1M to 775.5M.
- What is the long-term trend for Summit Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Summit Therapeutics's shares (diluted) has grown at a 64.5% compound annual growth rate (CAGR), from 405.6M to 3B.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Summit Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude